Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Strong cross-read from Roche's PathAI takeover Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia secures landmark hospital group as sole AI provider Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Clinical growth accelerates, roadmap to scale is clear Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY H2'25 preview; accelerating clinical revenue growth expected Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia's tech advances to expedite path to profitability Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Cap hike to ease short-term liquidity constraints; BUY Aiforia Technologies Oyj: Roundtable für Investoren am 19.11.2025 Aiforia Technologies Oyj: Roundtable für Investoren am 17.11.2025 Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY